Advertisement
Advertisement

PGEN

PGEN logo

Precigen, Inc. Common Stock

4.15
USD
Sponsored
+0.07
+1.72%
May 13, 15:59 UTC -4
Closed
exchange

Pre-Market

4.82

+0.67
+16.14%

Precigen, Inc. Common Stock Profile

About

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Info & Links

CEO

Helen Sabzevari

Headquarters

20374 Seneca Meadows Parkway
Germantown, MD 20876, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.precigen.com

Auditor

Deloitte & Touche LLP

Share holders

271

Employees

160

Precigen, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

1.72B

Enterprise Value

1.78B

Enterprise Value/EBITDA(ttm)

-16.92

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

156.06

Price to Book(mrq)

72.25

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

30.00%

Operating Margin(ttm)

714.49%

Profit Margin(ttm)

-4699.95%

Return on Equity(ttm)

2317.96%

Return on Invested Capital(ttm)

-27.66%

Return on Assets(ttm)

49.65%

Income Statement

Revenue(ttm)

9.68M

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

4.86M

EBITDA(ttm)3

-105.25M

Net Income Available to Common(ttm)

-429.64M

Diluted EPS(ttm)

-1.34

Share Statistics

Beta (5Y Monthly)

1.12

52-Week Change

207.41%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

353.93M

Dividend Yield

0.00%

Float4

187.23M

% Held by Insiders

47.10%

% Held by Institutions

33.51%

Balance Sheet

Total Cash(mrq)

97.86M

Total Cash Per Share(mrq)

0.28

Total Debt(mrq)

93.17M

Total Debt/Equity(mrq)

445.57%

Current Ratio(mrq)

3.09%

Quick Ratio(mrq)

2.83%

Book Value Per Share(mrq)

0.06

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.28

Free Cash Flow(ytd)

-89.83M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement